Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma

A systematic review of survival following anti-cancer treatment for small cell lung cancer

(2020) Gavin S. Jones et al.   LUNG CANCER

Immunotherapeutic approaches for small-cell lung cancer

(2020) Wade T. Iams et al.   Nature Reviews Clinical Oncology

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.

(2020) Ticiana Leal et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

(2020) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research

(2020) Shanmuga Subbiah et al.   Journal of Clinical Medicine

Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

(2020) Koichi Ando et al.   Cancers

1799P Immune checkpoint inhibitor plus chemotherapy versus chemotherapy alone as first-line for extensive stage small cell lung cancer: A meta-analysis

(2020) T. Landre et al.   ANNALS OF ONCOLOGY

Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC)

(2020) Xiaoting Ma et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials

(2020) Francesco Facchinetti et al.   Cancers

The role of immunotherapy in small cell lung cancer

(2019) A. Calles et al.   Clinical & Translational Oncology

Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer

(2019) Jacob Franek et al.   Future Oncology

Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis

(2019) Abdulaali R. Almutairi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

(2019) Hyun Cheol Chung et al.   Journal of Thoracic Oncology

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Unravelling the biology of SCLC: implications for therapy

(2017) Joshua K. Sabari et al.   Nature Reviews Clinical Oncology

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

(2016) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

(2016) Andrew G. Nicholson et al.   Journal of Thoracic Oncology

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline

(2015) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement

(2013) L. C. Villaruz et al.   CLINICAL CANCER RESEARCH

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS

Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results

(2009) Isao Oze et al.   PLoS One